Shaw B W, Gordon R D, Iwatsuki S, Starzl T E
Semin Liver Dis. 1985 Nov;5(4):394-401. doi: 10.1055/s-2008-1040638.
Since the introduction of cyclosporine-prednisone for primary immunosuppression, retransplantation has become a feasible option for patients whose primary grafts are failing, which may result from primary graft nonfunction, intractable rejection, or consequent to technical complications. Although survival of patients requiring second grafts is less good than in those whose initial graft functions well, 2-year survival rates of 49% have been achieved in retransplanted patients, a record that mandates serious consideration of this approach when the primary graft begins to fail. In general, the retransplant procedure is technically easier, with less blood loss, than is the initial operation. When the reoperation is done electively, it should be done before serious clinical deterioration compromises the chances for success.
自从将环孢素 - 泼尼松用于初始免疫抑制以来,再次移植已成为原发性移植物功能衰竭患者的一种可行选择,原发性移植物功能衰竭可能是由原发性移植物无功能、难治性排斥反应或技术并发症导致的。尽管需要二次移植的患者的生存率不如初次移植物功能良好的患者,但再次移植患者已实现了49%的2年生存率,这一记录使得在原发性移植物开始功能衰竭时必须认真考虑这种方法。一般来说,再次移植手术在技术上比初次手术更容易,失血更少。当择期进行再次手术时,应在严重临床恶化影响成功机会之前进行。